# Frontier IP Trading update and Exscientia & Celgene drug discovery collaboration

- Link: https://www.directorstalkinterviews.com/frontier-ip-trading-update-and-exscientia-celgene-drug-discovery-collaboration/412770254
- Published: 2019-03-21T09:26:04+00:00
- Author: Charlotte Edwards

**Frontier IP** (LON:FIPP), a specialist in commercialising university intellectual
property, is pleased to provide an update on trading for the year ending 30 June
2019.

The Group has enjoyed a strong first half to the financial year and since the beginning
of 2019 there have been a number of positive portfolio updates as previously announced
by the Group. In addition, Frontier IP  today announced that Exscientia, a world
leader in AI-driven drug discovery, has secured a significant trade deal with Celgene
Corporation. This, combined with other progress Exscientia is making, is expected
to result in a substantial uplift in Frontier IP’s book value for its holding.

Whilst it is not possible for the Board to be certain on what the overall portfolio
valuation will be at 30 June 2019 and progress of early and development stage businesses
that constitute Frontier IP’s portfolio is inherently uncertain, based on the trading
for the year to date and the outlook for the remainder of the financial year the
Board anticipates that the outcome for the year ending 30 June 2019 will be ahead
of management expectations.

The Group will be releasing its interim results for the six months to 31 December
2018 by end of March 2019.

**Exscientia and Celgene enter three-year AI drug discovery collaboration to accelerate
drug discovery in oncology and autoimmunity**

**Frontier IP** (LON:FIPP), a specialist in commercialising university intellectual
property, is pleased to note today’s statement from portfolio company Exscientia(“
Exscientia” or the “Company) , a world leader in artificial intelligence (“AI”) 
drug discovery, announcing a three-year partnership with global biopharma company
Celgene Corporation.

The collaboration to accelerate drug discovery in oncology and autoimmunity includes
an initial US$25 million upfront payment to Exscientia. The Company is also eligible
to receive substantial milestones based on the clinical, regulatory and commercial
success of the programme, and is due to receive tiered royalties on net sales of
any product. The full text of Exscientia’s statement is below.

Frontier IP holds a 3.32 per cent stake in Exscientia.

> **Frontier IP chief executive officer Neil Crabb said:** “We’re delighted Exscientia
> continues to make such strong progress. Celgene joins an impressive list of collaboration
> agreements struck by Exscientia with global pharma groups, building on those already
> signed with Roche, GSK, Sanofi and Evotec.”

Share on:
